Nuclear exclusion of the PTEN (phosphatase and tensin homologue deleted in chromosome 10) tumour suppressor has been associated with cancer progression 1-6 . However, the mechanisms leading to this aberrant PTEN localization in human cancers are currently unknown. We have previously reported that ubiquitinylation of PTEN at specific lysine residues regulates its nuclearcytoplasmic partitioning 7 . Here we show that functional promyelocytic leukaemia protein (PML) nuclear bodies co-ordinate PTEN localization by opposing the action of a previously unknown PTEN-deubiquitinylating enzyme, herpesvirus-associated ubiquitin-specific protease (HAUSP, also known as USP7), and that the integrity of this molecular framework is required for PTEN to be able to enter the nucleus. We find that PTEN is aberrantly localized in acute promyelocytic leukaemia, in which PML function is disrupted by the PML-RARa fusion oncoprotein. Remarkably, treatment with drugs that trigger PML-RARa degradation, such as all-trans retinoic acid or arsenic trioxide, restore nuclear PTEN. We demonstrate that PML opposes the activity of HAUSP towards PTEN through a mechanism involving the adaptor protein DAXX (death domain-associated protein). In support of this paradigm, we show that HAUSP is overexpressed in human prostate cancer and is associated with PTEN nuclear exclusion. Thus, our results delineate a previously unknown PML-DAXX-HAUSP molecular network controlling PTEN deubiquitinylation and trafficking, which is perturbed by oncogenic cues in human cancer, in turn defining a new deubiquitinylation-dependent model for PTEN subcellular compartmentalization.
Nuclear exclusion of the PTEN (phosphatase and tensin homologue deleted in chromosome 10) tumour suppressor has been associated with cancer progression [1] [2] [3] [4] [5] [6] . However, the mechanisms leading to this aberrant PTEN localization in human cancers are currently unknown. We have previously reported that ubiquitinylation of PTEN at specific lysine residues regulates its nuclearcytoplasmic partitioning 7 . Here we show that functional promyelocytic leukaemia protein (PML) nuclear bodies co-ordinate PTEN localization by opposing the action of a previously unknown PTEN-deubiquitinylating enzyme, herpesvirus-associated ubiquitin-specific protease (HAUSP, also known as USP7), and that the integrity of this molecular framework is required for PTEN to be able to enter the nucleus. We find that PTEN is aberrantly localized in acute promyelocytic leukaemia, in which PML function is disrupted by the PML-RARa fusion oncoprotein. Remarkably, treatment with drugs that trigger PML-RARa degradation, such as all-trans retinoic acid or arsenic trioxide, restore nuclear PTEN. We demonstrate that PML opposes the activity of HAUSP towards PTEN through a mechanism involving the adaptor protein DAXX (death domain-associated protein). In support of this paradigm, we show that HAUSP is overexpressed in human prostate cancer and is associated with PTEN nuclear exclusion. Thus, our results delineate a previously unknown PML-DAXX-HAUSP molecular network controlling PTEN deubiquitinylation and trafficking, which is perturbed by oncogenic cues in human cancer, in turn defining a new deubiquitinylation-dependent model for PTEN subcellular compartmentalization.
Although originally thought to function solely in the cytoplasm, there is now compelling evidence that nuclear PTEN is also essential for tumour suppression [7] [8] [9] [10] [11] . To our surprise, we observed that acute promyelocytic leukaemia (APL) biopsies harbouring the t(15; 17) chromosomal translocation, encoding the PML-RARa fusion protein, exhibited a predominantly cytoplasmic PTEN distribution ( Fig. 1a and Supplementary Fig. 1 ; see Methods and Supplementary Fig. 2 for PTEN antibody specificity). APL is commonly treated with all-trans retinoic acid (ATRA), an agent that induces degradation of PML-RARa and restores PML nuclear bodies ( Fig. 1b (inset) and Supplementary Fig. 3c , 4a and 5a, b and ref. 12 ). Examination of APL biopsies and NB4 cells before and after ATRA treatment demonstrated that ATRA effectively restored nuclear PTEN (Fig. 1b, c and Supplementary Figs 3a, b and 4a) with no effect on total PTEN levels ( Supplementary Fig. 5b , c). Like ATRA, arsenic trioxide (ATO) is a common therapy for APL, causing a biphasic effect on PML nuclear bodies; short-term treatment promotes the selective proteasome-dependent degradation of PML-RARa fusion protein and recovery of nuclear bodies, whereas long exposure induces the degradation of PML and the consequent disassembly of the nuclear bodies [13] [14] [15] . Indeed, this was observed on treatment of NB4 cells with this ATO; specifically, 4 h of treatment reconstituted nuclear bodies and restored PTEN localization to the nucleus, whereas the nuclear bodies were abolished at 24 h of treatment with a concomitant cytoplasmic PTEN localization ( Fig. 1c, d and Supplementary Figs 4 and 5), with no significant change of PTEN protein levels ( Supplementary Fig. 5b ). Furthermore, ATRA did not relocalize PTEN to the nucleus in ATRA-resistant NB4 (NB4R) cells, whereas ATO could control PTEN localization in NB4R as well as in ATRA-sensitive cells ( Fig. 1d and Supplementary Fig. 4b ).
To validate our findings, we used the MRP8-PML-RARa (transgenic) mouse model of APL, in which Pten is predominantly cytoplasmic in pre-neoplastic compared to wild-type promyelocytes ( Fig. 1e ). Notably, ATRA restored nuclear localization of Pten in transgenic promyelocytes ( Fig. 1e) .
To demonstrate the specificity of PML-RARa on Pten, Pml 1/2 mouse embryonic fibroblasts (MEFs) were transduced with a retrovirus expressing PML-RARa. Indeed PML-RARa was effective at driving nuclear exclusion of Pten ( Supplementary Fig. 6a , b), and ATRA treatment restored nuclear Pten ( Supplementary Fig. 6c, d ). This demonstrates that disassembly of the PML nuclear bodies by PML-RARa can alter Pten localization. Because Pml is essential for proper nuclear body formation 16 , we analysed the localization of Pten in wild-type and Pml-null MEFs. In Pml-null MEFs, the fraction of cytoplasmic Pten was significantly increased ( Fig. 1f and Supplementary Fig. 6e , f) and accompanied by a slight reduction of Pten expression levels ( Supplementary Fig. 6f , right panel). Notably, ATRA treatment of NB4 cells induced an enrichment of PTEN in well-defined nuclear structures that co-localized with PML ( Supplementary Fig. 7a ). Moreover, PTEN co-localized to nuclear bodies in wild-type, but not Pml-null, MEFs ( Supplementary Fig.  7b ). These results are the first, to our knowledge, to highlight a role for PML and PML nuclear bodies in the regulation of PTEN localization and imply that disrupted PTEN localization may have relevance in malignancies in which PML and PML nuclear bodies are compromised as in APL.
Similar to other tumour suppressors such as FOXO4 and p53, PTEN localization can be modulated by ubiquitinylation 17 . Strikingly, ATRA treatment increased Pten monoubiquitinylation in NB4 cells ( Fig. 2a ). Moreover, cells lacking Pml displayed reduced levels of Pten monoubiquitinylation ( Supplementary Fig. 7c ) and reduced nuclear Pten ( Fig. 1f and Supplementary Fig. 6e ).
To identify the means by which PML nuclear bodies regulate PTEN ubiquitinylation, we focused our attention on nuclear-bodyassociated proteins that may modulate ubiquitinylation. HAUSP has been reported to co-localize to the nuclear bodies, and to critically regulate protein localization through ubiquitinylation 18 . Indeed, Hausp localized to Pml nuclear bodies ( Supplementary Fig. 7d ) and co-immunoprecipitated with Pml ( Supplementary Fig. 7e ). Moreover, ATRA treatment re-localized HAUSP to PML nuclear bodies ( Supplementary Fig. 7f ).
Next, by examining the physical and functional interactions between PTEN and HAUSP, we found that they interact directly (Fig. 2b, c and Supplementary Fig. 8a ). Importantly, through its enzymatic activity, HAUSP reduced PTEN monoubiquitinylation ( Fig. 2d and Supplementary Fig. 8b ), because the catalytically inactive (CS) HAUSP mutant, which can bind to PTEN (Supplementary Fig. 8c ), did not reduce the levels of PTEN monoubiquitinylation. Additionally, RNA interference (RNAi) knockdown of HAUSP increased PTEN monoubiquitinylation ( Fig. 2e and Supplementary  Fig. 8d ). Therefore, these findings uncover HAUSP as the first bona fide PTEN deubiquitinylase (DUB). Monoubiquitinylation has been suggested to be a 'key' for proteins to gain access into other cellular compartments [19] [20] [21] . We found that HAUSP overexpression resulted in the nuclear exclusion of PTEN (Fig. 3a, b and Supplementary Fig. 9a, b) . Notably, forced monoubiquitinylation of PTEN with lysine-free ubiquitin (KØ-Ub), which displays mostly nuclear localization, was rendered predominantly cytoplasmic on HAUSP overexpression ( Fig. 3c and Supplementary Fig. 9c ). Conversely, RNAi knockdown of HAUSP rendered PTEN mainly nuclear (Fig. 3d, e and Supplementary Fig. 9d ), in agreement with the notion that monoubiquitinylated PTEN is nuclear ( Fig. 2d, e, Supplementary Fig. 8b, d and ref. 7) . Furthermore, in HAUSP-null HCT116 colon carcinoma cells 22 , PTEN localization was predominantly nuclear compared to that in parental HCT116 cells (Fig. 3f, g) .
Because Lys 289 and Lys 13 are the major residues for PTEN ubiquitinylation 7 , we used cytoplasmic green fluorescent protein (GFP)-PTEN mutants to examine HAUSP activity on these sites ( Supplementary Figs 10 and 11) . Surprisingly, HAUSP silencing or deletion rendered PTEN(K289E) and PTEN(K13E), but not PTEN(K13,K289E), predominantly nuclear ( Supplementary Figs  10a, b and 11a, d) . In agreement, co-expression with KØ-Ub promoted PTEN(K289E) and PTEN(K13E), but not PTEN(K13,K289E), nuclear localization ( Supplementary Figs 10c, d and 11b , c, e, f). HAUSP overexpression re-localized PTEN(K289E) and PTEN(K13E) to the cytoplasm, suggesting that monoubiquitinylation/deubiquitinylation of one of either site is sufficient to modulate PTEN comportmentalization. (Supplementary Figs 10c, d and 11b, c) .
Nuclear exclusion of PTEN has been associated with more aggressive or late-stage cancers, suggesting that cytoplasmic PTEN lacks full tumour suppressive function 1-6 . To address the role of nuclear PTEN in tumour suppression, we expressed GFP-tagged wild-type PTEN or PTEN(K13,K289E) in (PTEN-null) PC3 prostate cancer cells and analysed apoptosis by TUNEL and annexin V ( Supplementary Fig.  11g and data not shown). As expected, PTEN expression increased apoptosis relative to control cells, which was further increased by its forced monoubiquitinylation. However, PTEN(K13,289E) overexpression resulted in a lower apoptotic index and did not increase the apoptosis on co-expression of KØ-Ub. These results support the notion that nuclear-excluded PTEN has a decreased apoptotic potential, and therefore less tumour suppressive ability. These findings are of great relevance because the HAUSP/PTEN regulatory network is frequently aberrant in human prostate cancer (see below).
Our results demonstrate that deubiquitinylation of PTEN by HAUSP has a crucial role in PTEN localization and function, which implies that alterations in the levels of PTEN DUBs may account for the nuclear exclusion of PTEN observed in many cancers. Indeed, we found that HAUSP is overexpressed in prostate cancer, and, more importantly, high levels of HAUSP are directly correlated with tumour aggressiveness ( Supplementary Fig. 12 ). Moreover, the association between HAUSP levels and PTEN localization indicated the existence of a direct relationship (P , 0.000008; x 2 -test) between HAUSP levels and nuclear exclusion of PTEN (Fig. 3h ). These results are the first to report that HAUSP is overexpressed in cancer and directly associated with tumour aggressiveness. Furthermore, the correlation with PTEN localization lends support to the notion that overexpression of this DUB impacts on the correct localization of the tumour suppressor PTEN, and therefore on tumorigenesis.
Collectively, our findings led us to hypothesize that PML and HAUSP exert opposite functions with respect to PTEN monoubiquitinylation and localization. Indeed, the ability of HAUSP overexpression to localize PTEN to the cytoplasm was markedly inhibited by co-overexpression of PML, such that PTEN was predominantly localized to the nucleus (Fig. 4a ) and partially co-localized with PML and HAUSP ( Supplementary Fig. 13a ). Furthermore, PML, but not PML-RARa, was able to inhibit the deubiquitinylation of PTEN observed on HAUSP overexpression alone ( Fig. 4b and Supplementary Fig. 13b ). Similarily, Hausp silencing in Pml-null MEFs restored a wild-type-like distribution of Pten ( Fig. 4c and Supplementary Fig. 13c ). Overall, we have identified a previously unknown pathway by which PML regulates PTEN compartmentalization through the inhibition of HAUSP-mediated deubiquitinylation. To elucidate the mechanism by which PML opposes HAUSP function towards PTEN, we examined the consequences of expression of three different PML-mutant proteins on PTEN localization ( Supplementary Fig. 14a) . Surprisingly, sumoylation-deficient PML species, which have been shown to form non-functional nuclear bodies 23 , were unable to localize PTEN to the nucleus compared to the wild-type control and a PML RING domain mutant (PML-CS; C57S,C60S, Supplementary Fig. 14b ). This suggests that the presence of functional nuclear bodies is requisite for HAUSP function. On this basis, we focused on DAXX, a nuclear-body-residing protein that has been demonstrated to modulate HAUSP function 24, 25 and is not repressed by the sumoylation-defective PML mutants 26 . Indeed, DAXX overexpression led to cytoplasmic PTEN localization ( Fig. 4d and Supplementary Fig. 15a) whereas DAXX silencing increased the nuclear fraction of PTEN ( Fig. 4e and Supplementary  Fig. 15b ).
Taken together, our findings have allowed us to reach a number of relevant conclusions. First, we have identified HAUSP as a critical and essential enzyme for PTEN deubiquitinylation and subcellular localization. Nuclear exclusion of PTEN is associated with a more aggressive cancers 1, 7 . Also, PTEN has been proposed to regulate genomic stability from the nucleus 9 , and it can oppose anchorage-independent growth 27 . In line with this idea, our data show that monoubiquitinylated PTEN, which is mainly nuclear, possesses greater apoptotic potential. This suggests that the tumour suppressive activity of PTEN is at least in part due to its ability to reside in the nucleus. Until now, only the E3-ligase NEDD4-1 has been reported to ubiquitinylate PTEN 28 , although additional E3 ligases certainly serve this purpose. Consequently, the notion of ubiquitin-dependency for localization implies that other enzymes capable of deubiquitinylating PTEN may also have an important role in PTEN localization. Therefore, the identification of HAUSP as a critical DUB for PTEN subcellular localization lends strong support to the notion that cellular localization of PTEN is controlled by its ubiquitinylation status.
Second, we propose a new model for PTEN trafficking (Fig. 4f ) whereby in physiological conditions PTEN ubiquitinylation by E3ligases allows PTEN to accumulate in the nucleus, whereas PTEN deubiquitinylation by HAUSP favours PTEN accumulation in the cytoplasm. According to this model, PML has a critical regulatory role by inhibiting HAUSP activity through DAXX, which in turn favours PTEN nuclear localization.
Finally, these findings have important implications for cancer because the new regulatory network we have identified can be perturbed at multiple levels in oncogenic conditions (Fig. 4f ). First, HAUSP overexpression leads to a predominantly nuclear-excluded PTEN. The fact that this phenotype is associated with more aggressive prostate cancer implies that HAUSP may behave as an oncogene when aberrantly expressed through its ability to disrupt PTEN function through delocalization. Second, this network includes the tumour suppressor PML, suggesting that PTEN delocalization may be an important consequence in PML-loss-associated cancers 19 . Third, as PTEN is excluded from the nucleus of APL blasts, loss of PTEN nuclear function could have a role in the pathogenesis of this and possibly other forms of leukaemia. The identification of such a network and its deregulated hubs in human cancers will ultimately allow the development of drugs that restore normal PTEN localization towards effective therapy, as epitomized by ATRA and ATO treatment in APL cells.
METHODS SUMMARY
Cell culture. All MEFs were prepared from embryos at day 13.5 of development (E13.5). Early passage (P2-P5) MEFs or SV40 immortalized MEFs were used in all experiments, except as indicated. NB4 cells, a human APL cell line bearing the t(15; 17), and ATRA-resistant NB4 (NB4R) cells were a gift from M. Lanotte. HAUSP 1/1 and HAUSP -/-HCT116 cells were provided by B. Vogelstein. ATRA (Sigma) and ATO (Sigma) were prepared at a concentration of 1 mmol l 21 in PBS and 10 mol l 21 in NaOH, respectively. Promyelocytes were isolated by flushing the femur and tibia bone marrow and collected by magnetic separation with anti-CD11b and anti-Gr-1. Antibodies. The following antibodies were used: PTEN (for IF/IHC, 6H2.1, Cascade Bioscience; for immunoblot, Cell Signaling), PML (Ab1370, MAB3738, Chemicon; H-238, Santa Cruz;), HAUSP (Bethyl Laboratories), Myc (Cell Signaling), Flag (Sigma), DAXX (Santa Cruz), lamin B1 (Abcam), Hsp90 (BD Transduction Laboratories), RARa (Affinity Bioreagents), b-actin (Sigma), glutathione S-transferase (Santa Cruz), haemagglutinin (Covance) and ubiquitin (BD Pharmingen; Biomol International). Immunoblotting, immunofluorescence, co-immunoprecipitation and the in vitro binding assay were performed with these antibodies as described 7 .
Immunohistochemistry on patient samples and tumour tissue microarrays. Prostate tumour tissue microarrays were constructed using a fully automated Beecher Instrument, ATA-27. The study cohort comprised APL and prostate tumours consecutively ascertained at the Memorial Sloan-Kettering Cancer Center (MSKCC). All biopsies were evaluated at MSKCC, and the histological diagnosis was based on established criteria. Nuclear/cytoplasmic fractionation. Nuclear/cytoplasmic fractionation was performed as described 7 . Nuclear to cytoplasmic ratios were calculated using the following densities (PTEN-nuc/lamin B)/(PTEN-cyto/Hsp90). Ubiquitinylation assays. In vivo ubiquitinylation was performed as described 7 .
Immunoprecipitates with anti-PTEN were washed twice with 0.5 M LiCl in TBS and twice with TBS, and then resolved by SDS-PAGE. In vitro ubiquitinylation was performed as described 7 . Statystical analysis. Statistical significance was evaluated by using the Student's t-test and x 2 analysis when required.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
